Skip to main content
Erschienen in: Tumor Biology 11/2014

01.11.2014 | Research Article

RETRACTED ARTICLE: Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma

verfasst von: Shunli Liu, Zhenyu Gong, Mingrui Chen, Benli Liu, Donghui Bian, Kai Wu

Erschienen in: Tumor Biology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Cancer stem cells (CSCs) in most human tumors are commonly identified and enriched using similar strategies for identifying normal stem cells, including flow cytometry assays for side population, high aldehyde dehydrogenase (ALDH) activity, and CD133 positivity. Thus, development of a method for isolating a specific cancer using cancer-specific characteristic appears to be potentially important. Here, we reported extremely high Lgr5 levels in the specimen from skin squamous cell carcinoma (SCC) in patients. Using SCC cell line A431, we detected high Lgr5 and CD133 levels in ALDH-high or side population from these cancer cells. To figure out whether Lgr5 is a marker of CSCs in SCC, we transfected A431 cells with a Lgr5-creERT-2A-DTR/Cag-Loxp-GFP-STOP-Loxp-RFP plasmid and purified transfected cells (tA431) based on GFP by flow cytometry. 4-Hydroxytamoxifen (4-OHT) was given to label Lgr5-positive cells with RFP, for comparison to GFP-positive Lgr5-negative cells. Lgr5-positive cells grew significantly faster than Lgr5-negative cells, and the fold increase in growth of Lgr5-positive vs Lgr5-negative cells is significantly higher than SP vs non-SP, or ALDH-high vs ALDH-low, or CD133-positive vs CD133-negative cells. Moreover, in Lgr5-negative population, Lgr5-positive re-appeared in culture with time, suggesting that Lgr5-positive cells can be regenerated from Lgr5-negative cells. Furthermore, the growth of tA431 cells significantly decreased upon a single dose of diphtheria toxin (DT)/4-OHT to eliminate Lgr5-positive cell lineage, while multiple doses of DT/4-OHT nearly completely inhibited tA431 cell growth. Taken together, our data provide compelling data to demonstrate that Lgr5-positive cells are CSCs in skin SCC.
Literatur
1.
Zurück zum Zitat Rahimi S. Squamous cell carcinoma of skin: a brief review. Clin Ter. 2013;164:143–7.PubMed Rahimi S. Squamous cell carcinoma of skin: a brief review. Clin Ter. 2013;164:143–7.PubMed
2.
Zurück zum Zitat Petersson M, Niemann C. Stem cell dynamics and heterogeneity: implications for epidermal regeneration and skin cancer. Curr Med Chem. 2012;19:5984–92.CrossRefPubMed Petersson M, Niemann C. Stem cell dynamics and heterogeneity: implications for epidermal regeneration and skin cancer. Curr Med Chem. 2012;19:5984–92.CrossRefPubMed
3.
Zurück zum Zitat Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer. 2003;3:434–43.CrossRefPubMed Perez-Losada J, Balmain A. Stem-cell hierarchy in skin cancer. Nat Rev Cancer. 2003;3:434–43.CrossRefPubMed
4.
Zurück zum Zitat Nagata T, Sakakura C, Komiyama S, Miyashita A, Nishio M, Murayama Y, et al. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 2011;31:495–500.PubMed Nagata T, Sakakura C, Komiyama S, Miyashita A, Nishio M, Murayama Y, et al. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer. Anticancer Res. 2011;31:495–500.PubMed
5.
Zurück zum Zitat Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, Mesmer D, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer. 2010;102:1265–75.CrossRefPubMedPubMedCentral Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, Mesmer D, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer. 2010;102:1265–75.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;10:1182–90.CrossRefPubMed Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;10:1182–90.CrossRefPubMed
7.
Zurück zum Zitat Ottaiano A. Finding markers for cancer stem cells in renal cell carcinoma: looking beyond CD133. Cell Cycle. 2010;9:4431.CrossRefPubMed Ottaiano A. Finding markers for cancer stem cells in renal cell carcinoma: looking beyond CD133. Cell Cycle. 2010;9:4431.CrossRefPubMed
8.
Zurück zum Zitat Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6:1146–53.CrossRefPubMed Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res. 2008;6:1146–53.CrossRefPubMed
9.
Zurück zum Zitat Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122:761–8.CrossRefPubMed Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008;122:761–8.CrossRefPubMed
10.
Zurück zum Zitat Takubo K, Ohmura M, Azuma M, Nagamatsu G, Yamada W, Arai F, et al. Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest. Cell Stem Cell. 2008;2:170–82.CrossRefPubMed Takubo K, Ohmura M, Azuma M, Nagamatsu G, Yamada W, Arai F, et al. Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest. Cell Stem Cell. 2008;2:170–82.CrossRefPubMed
11.
Zurück zum Zitat Duester G. Families of retinoid dehydrogenases regulating vitamin a function: production of visual pigment and retinoic acid. Eur J Biochem. 2000;267:4315–24.CrossRefPubMed Duester G. Families of retinoid dehydrogenases regulating vitamin a function: production of visual pigment and retinoic acid. Eur J Biochem. 2000;267:4315–24.CrossRefPubMed
12.
Zurück zum Zitat Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996;87:1097–103.PubMed Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood. 1996;87:1097–103.PubMed
13.
Zurück zum Zitat Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells. 2004;22:1142–51.CrossRefPubMed Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells. 2004;22:1142–51.CrossRefPubMed
14.
Zurück zum Zitat Hess DA, Craft TP, Wirthlin L, Hohm S, Zhou P, Eades WC, et al. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells. 2008;26:611–20.CrossRefPubMed Hess DA, Craft TP, Wirthlin L, Hohm S, Zhou P, Eades WC, et al. Widespread nonhematopoietic tissue distribution by transplanted human progenitor cells with high aldehyde dehydrogenase activity. Stem Cells. 2008;26:611–20.CrossRefPubMed
15.
Zurück zum Zitat Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004;104:1648–55.CrossRefPubMed Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004;104:1648–55.CrossRefPubMed
16.
Zurück zum Zitat Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 2006;107:2162–9.CrossRefPubMedPubMedCentral Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 2006;107:2162–9.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Liu Y, Jiang X, Zeng Y, Zhou H, Yang J, Cao R: Proliferating pancreatic beta-cells upregulate ALDH. Histochem Cell Biol 2014 Liu Y, Jiang X, Zeng Y, Zhou H, Yang J, Cao R: Proliferating pancreatic beta-cells upregulate ALDH. Histochem Cell Biol 2014
18.
Zurück zum Zitat Zhang L, Wang L, Liu X, Zheng D, Liu S, Liu C. ALDH expression characterizes G1-phase proliferating beta cells during pregnancy. PLoS ONE. 2014;9:e96204.CrossRefPubMedPubMedCentral Zhang L, Wang L, Liu X, Zheng D, Liu S, Liu C. ALDH expression characterizes G1-phase proliferating beta cells during pregnancy. PLoS ONE. 2014;9:e96204.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991–4001.CrossRefPubMedPubMedCentral Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991–4001.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011;7:292–306.CrossRefPubMed Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011;7:292–306.CrossRefPubMed
21.
Zurück zum Zitat Kinzel B, Pikiolek M, Orsini V, Sprunger J, Isken A, Zietzling S, et al. Functional roles of Lgr4 and Lgr5 in embryonic gut, kidney and skin development in mice. Dev Biol. 2014;390:181–90.CrossRefPubMed Kinzel B, Pikiolek M, Orsini V, Sprunger J, Isken A, Zietzling S, et al. Functional roles of Lgr4 and Lgr5 in embryonic gut, kidney and skin development in mice. Dev Biol. 2014;390:181–90.CrossRefPubMed
23.
Zurück zum Zitat Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593–605.CrossRefPubMed Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593–605.CrossRefPubMed
24.
Zurück zum Zitat Xiao X, Chen Z, Shiota C, Prasadan K, Guo P, El-Gohary Y, et al. No evidence for beta cell neogenesis in murine adult pancreas. J Clin Invest. 2013;123:2207–17.CrossRefPubMedPubMedCentral Xiao X, Chen Z, Shiota C, Prasadan K, Guo P, El-Gohary Y, et al. No evidence for beta cell neogenesis in murine adult pancreas. J Clin Invest. 2013;123:2207–17.CrossRefPubMedPubMedCentral
Metadaten
Titel
RETRACTED ARTICLE: Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma
verfasst von
Shunli Liu
Zhenyu Gong
Mingrui Chen
Benli Liu
Donghui Bian
Kai Wu
Publikationsdatum
01.11.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 11/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2488-6

Weitere Artikel der Ausgabe 11/2014

Tumor Biology 11/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.